This document is the September 2025 newsletter (Volume 19, Issue 9) published by the Egyptian Pharmacovigilance Center (EPVC), which operates under the Egyptian Drug Authority (EDA).
The central theme of the newsletter is medication safety, focusing on educating healthcare professionals and the public about the detection, understanding, and prevention of adverse effects and medication errors. It serves as a crucial communication tool to promote safe and effective medicine use in Egypt.
Here is a detailed breakdown of its contents:
1. EPVC Mission and Introduction
The newsletter begins by stating the mission of the Pharmaceutical Vigilance administration, which is to oversee the authorization, regulation, monitoring, and evaluation of the safety of all pharmaceutical products and medical devices in Egypt. Its goal is to disseminate safety information to protect public health.
2. Main Content Sections
A. Prescriber Update: BRASH Syndrome
- Topic: This article educates healthcare providers about a dangerous clinical condition called BRASH syndrome.
- What is BRASH Syndrome? It is a vicious cycle where the combination of Bradycardia (slow heart rate), Renal failure, AV nodal blockers (a type of heart medication), Shock, and Hyperkalemia (high potassium) leads to severe health deterioration.
- Key Message: The bradycardia in BRASH is more profound than what would be expected from either hyperkalemia or the heart medications alone. It is a dangerous synergy.
- Associated Medicines: The article specifically links BRASH syndrome to calcium channel blockers (e.g., diltiazem) and beta-blockers (e.g., propranolol), and notes that other drugs affecting kidney function or potassium levels (like ACE inhibitors, ARBs, spironolactone) can contribute.
- Purpose: To raise awareness and encourage reporting of this syndrome, which is a newly recognized entity in pharmacovigilance.
B. Local Case Safety Report: Methotrexate Toxicity
- Topic: A detailed analysis of a serious and life-threatening medication error involving Methotrexate, a drug used for Rheumatoid Arthritis.
- The Error: An elderly female patient was incorrectly prescribed Methotrexate 50 mg daily instead of the correct once-weekly regimen. This led to severe toxicity.
- Clinical Consequences: The patient experienced acute gastrointestinal toxicity (vomiting, diarrhea, abdominal pain), dehydration, metabolic acidosis, severe pancytopenia (a sharp drop in all blood cells), shock, and required ICU admission with mechanical ventilation.
- Educational Focus:
- Explains the mechanism of Methotrexate and why its dosing is critical.
- Details the risk factors and clinical manifestations of its toxicity.
- Outlines the management protocol, which includes stopping the drug, administering Folinic Acid (Leucovorin) as an antidote, hydration, and supportive care.
- Provides strong recommendations for healthcare professionals (prescribers and pharmacists) to always write “once weekly” and to counsel patients extensively to prevent such fatal errors.
C. EPVC News: Initiatives and Updates
This section highlights the EPVC’s ongoing programs to strengthen pharmacovigilance in Egypt:
- “Together For Safer Medicine” Initiative: Celebrates the 7th wave of participants from pharmacies who are moving to the practical application phase of pharmacovigilance in their workplaces.
- VigiTest Competition: An ongoing monthly and annual competition designed to test and sharpen the pharmacovigilance knowledge of healthcare professionals, encouraging continuous learning.
- BE-Vigilant Initiative (2025-2026): A national program to build the capacity of pharmacovigilance “focal points” in healthcare facilities. It highlights participation from the Supreme Council of University Hospitals (SCOUH) and praises specific hospitals and governorates (like Ismailia and Luxor) for their outstanding awareness campaigns and case reporting.
D. EPVC Tips: Public Education on Drug Toxicity
- Topic: A simplified, public-facing explanation of drug toxicity.
- Content: It explains what drug toxicity is, how it can happen (overdose, long-term use, kidney/liver problems, drug interactions), what warning signs to watch for (unusual tiredness, stomach upset, yellowing skin, etc.), and what actions to take (never self-adjust doses, report symptoms immediately).
E. Call to Action and Reporting Information
- The final page is a direct call for reporting any suspected adverse drug reactions.
- It reiterates the definition of Pharmacovigilance and provides all necessary contact information for the EPVC, including:
- Hotline: 15301
- Email: pv.followup@edaegypt.gov.eg
- Online Reporting Link
- Physical Address
Summary
In essence, this newsletter is a comprehensive pharmacovigilance tool that:
- Educates on specific and emerging drug safety issues (BRASH syndrome).
- Analyses and Learns from a real-life, severe local case of a medication error (Methotrexate toxicity) to prevent future occurrences.
- Engages and Builds Capacity within the healthcare community through initiatives and competitions (Together for Safer Medicine, VigiTest, BE-Vigilant).
- Informs the Public about basic drug safety principles (EPVC Tips).
- Promotes Reporting by providing clear channels for healthcare professionals and the public to submit safety concerns.
The overarching goal is to create a collaborative environment where everyone works “Together For Safer Medicine” in Egypt.
